comparemela.com

Latest Breaking News On - Jiangsu hengrui pharmaceuticals co ltd - Page 1 : comparemela.com

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

Rivoceranib plus camrelizumab maintained a survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.

CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates

GSK Plc Completes Acquisition Of Aiolos Bio

GSK Plc Completes Acquisition Of Aiolos Bio
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

GSK completes acquisition of Aiolos Bio for up to $1 4 bln

GSK said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions. GSK will pay $1.

GSK completes acquisition of Aiolos Bio for up to $1 4 billion

GSK said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions. GSK will pay $1 billion upfront and up to $400 million in success-based milestone payments. "In addition, GSK will also be responsible for success-based milestone payments as well as tiered royalties owed to Jiangsu Hengrui Pharmaceuticals Co, Ltd," the group said.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.